ESC 365 - Antiplatelet therapy in high bleeding risk patients with and without oral anticoagulant therapy after coronary stenting

ESC Premium Access

Antiplatelet therapy in high bleeding risk patients with and without oral anticoagulant therapy after coronary stenting

Session: Trial Updates in ACS & PCI

Topic: Adjunctive Pharmacotherapy

Speaker: Doctor P. Smits (Rotterdam, NL)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Pieter C Smits

Maasstad Hospital, Rotterdam (Netherlands (The))

4 presentations

0 follower

2 more presentations in this session

SYNTAX II trial: five year follow-up

Speaker: Professor A. Banning (Oxford, GB)

TWILIGHT-HBR: Ticagrelor Monotherapy in High Bleeding Risk Patients

Speaker: Doctor D. Cao (Bergamo, IT)

Access the full session

Trial Updates in ACS & PCI

Speakers: Doctor P. Smits, Professor A. Banning, Doctor D. Cao

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

EHRA Premium Access

Hot topics in atrial fibrillation.

5 April 2022

ESC Premium Access

Choosing wisely: ablation or medication for rhythm control in atrial fibrillation – discussion.

27 August 2021

ESC Premium Access

Ablation or amiodarone for HFrEF patients with atrial fibrillation?

27 August 2021

ESC 365 is supported by